Allergy/Imm

sponsor

Topics in Allergy/Imm

Allergy/Anaphylaxis

Basic Science/Genetics

Cardiovascular/Pulm

Clinical Pharmacology

Derm Allergy/Immunology

Diagnostics/Radiology

Economics of Medicine

Gastrointestinal/Hepatic

HIV/Immunodeficiency

Hematology/Oncology

Maternal Fetal Medicine

Nephrology/Urology

Neurologic/Ophthalmic

Peds Allergy/Immunology

Rheumatic/Autoimmune

Surgery/Transplantation

Vaccine/Immunotherapy

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. 2008 Exclusive Survey—Earnings: Good news for primary care income

3. Medicare pay-for-reporting effort draws fire from frustrated doctors

4. Debunking Myths in the US Healthcare System

5. Novel therapies for children with severe asthma

Top Ten Searches

hla

beta 2

probiotics

hypo allergenic

scid

urticaria

aeroallergens

asthma

angioedema

hiv

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Treatment of patients with new onset Type 1 diabetes with a single course of anti-CD3 mAb teplizumab preserves insulin production for up to 5 years
Clinical Immunology, 07/28/09

Herold KC et al. – The authors conclude that increased doses of Teplizumab are associated with greater adverse events without improved efficacy. The drug may marginate rather than deplete T cells. C–peptide levels may remain detectable up to 5 years after treatment.

<< Previous
AMA backs House health system reform bill that includes Medicare...

Next >>
Genetic Backgrounds of Asthma and COPD

Today in Clinical Pharmacology...keeping you current

Hypersensitivity reactions to mAbs: 105 desensitizations in 23 patients, from evaluation to treatment
Journal of Allergy and Clinical Immunology, 11/25/09

Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma
Journal of Allergy and Clinical Immunology, 11/25/09

High doses of inhaled corticosteroids during the first trimester of pregnancy and congenital malformations
Journal of Allergy and Clinical Immunology, 11/25/09

See all of Clinical Pharmacology

Today in Endocrine...keeping you current

Treatment with the PPAR-gamma agonist rosiglitazone down-regulates interleukin-1 receptor antagonist in individuals with metabolic syndrome
European Journal of Endocrinology, 11/24/09

Autoimmune Polyglandular Syndrome Type 2 With Myasthenia Gravis Crisis
The Neurologist, 11/20/09

Diabetes associated with autoimmune pancreatitis: new insights into the mechanism of beta-cell dysfunction
Expert Review of Endocrinology & Metabolism, 11/17/09

See all of Endocrine

Sponsor

Article Search

Sponsor

Send this Summary to a Colleague